Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 15/20 | 0.59 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | FBP1 | P09467 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.55 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26321 | 0.87 | EGFR (0.64) | EGFRERBB2MAPK1FBP1HTT | |
| SCHEMBL1418279 | 0.87 | EGFR (0.77) | EGFRFBP1 | |
| SCHEMBL7811124 | 0.87 | EGFR (0.77) | EGFRERBB2MAPK1FBP1HTT | |
| SCHEMBL6506351 | 0.87 | EGFR (0.67) | EGFRERBB2MAPK1FBP1HTT | |
| SCHEMBL4968393 | 0.87 | EGFR (0.67) | EGFRERBB2FBP1ABCG2 | |
| Hydrochloric Acid SCHEMBL7809280 | 0.86 | EGFR (0.75) | EGFRERBB2MAPK1FBP1HTT | |
| SCHEMBL8315497 | 0.86 | EGFR (0.79) | EGFRERBB2MAPK1FBP1HTT | |
| SCHEMBL8088219 | 0.85 | EGFR (0.79) | EGFRERBB2MAPK1FBP1HIF1A | |
| SCHEMBL8871114 | 0.85 | EGFR (0.59) | EGFRERBB2MAPK1FBP1HTT | |
| SCHEMBL29614991 | 0.84 | EGFR (0.58) | EGFRERBB2FBP1ABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016023217-A1 | QUINAZOLINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | 安润医药科技（苏州）有限公司 | 2016-02-18 | — | — | WO | disclosed |
| US-7786131-B2 | Anticancer agents; restenosis; atherosclerosis; skin disorders | WARNER-LAMBERT COMPANY (US) | 2010-08-31 | — | — | US | disclosed |
| EP-0892789-B2 | IRREVERSIBLE INHIBITORS OF TYROSINE KINASES | WARNER LAMBERT CO (US) | 2009-11-18 | — | — | EP | disclosed |
| US-20030229051-A1 | Irreversible inhibitors of tyrosine kinases | BRIDGES ALEXANDER JAMES (US) | 2003-12-11 | — | — | US | disclosed |
| US-6602863-B1 | Irreversible inhibitors of tyrosine kinases | WARNER-LAMBERT COMPANY | 2003-08-05 | — | — | US | disclosed |
| EP-0892789-B1 | IRREVERSIBLE INHIBITORS OF TYROSINE KINASES | WARNER LAMBERT CO (US) | 2002-02-27 | — | — | EP | disclosed |
| US-6344459-B1 | TREATING CANCER, RESTENOSIS, ATHEROSCLEROSIS, ENDOMETRIOSIS, AND PSORIASIS | WARNER-LAMBERT COMPANY | 2002-02-05 | — | — | US | disclosed |
| EP-0635498-B1 | Quinazoline derivatives and their use as anti-cancer agents | SYNGENTA LTD (GB) | 2001-04-18 | — | — | EP | disclosed |
| EP-0892789-A1 | IRREVERSIBLE INHIBITORS OF TYROSINE KINASES | WARNER-LAMBERT COMPANY (US) | 1999-01-27 | — | — | EP | disclosed |
| WO-1997038983-A1 | IRREVERSIBLE INHIBITORS OF TYROSINE KINASES | WARNER-LAMBERT COMPANY (US) | 1997-10-23 | — | — | WO | disclosed |
| US-5475001-A | Quinazoline derivatives | ZENECA LIMITED (GB) | 1995-12-12 | — | — | US | disclosed |
| WO-1995003283-A1 | QUINAZOLINE DERIVATIVES AND THEIR USE AS ANTI-CANCER AGENTS | ZENECA LIMITED (GB) | 1995-02-02 | — | — | WO | disclosed |
| EP-0635498-A1 | Quinazoline derivatives and their use as anti-cancer agents | ZENECA LIMITED (GB) | 1995-01-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229051-A1 | Irreversible inhibitors of tyrosine kinases | ERBB2, ERBB3, LCK | EGFR 26/4885ERBB2 1/4885MAPK1 232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.